Abiopharma

🔍 Enders Thomas (Director)

Company: LINDE PLC (LIN)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 470 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,064.96 | transaction_form_type: 4 | Footnotes: F1
• Sold 51 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 11,013.89 | transaction_form_type: 4 | Footnotes: F2
• Acquired 473 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2027-03-09 | Exercise: 2027-03-09 | equity_swap_involved: 0 | shares_owned_after: 473.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Sold 470 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F5, F5

Footnotes:

• F1: Ordinary shares acquired pursuant to the payout of a restricted stock unit ("RSU") grant made on March 7, 2025.
• F2: Ordinary shares withheld from the payout to cover tax withholdings.
• F3: Conversion to Linde plc Ordinary Shares is on a 1-for-1 basis.
• F4: This RSU award will vest in full and payout on or about March 9, 2027, in Linde plc Ordinary Shares on a one-for-one basis, provided that the awardee serves on the Linde plc Board of Directors continuously through the vesting date, except under certain circumstances in which a pro-rata payout may be made.
• F5: The RSU award vested in full and paid out in Ordinary Shares on a one-for-one basis on March 9, 2026.